doi:10.1007/s00106-014-2979-1
So youll just have to plan both accordingly
Clinical pharmacology biopharmaceutics review: Mounjaro
Med Care 59(9):78994 Eberly LA, Yang L, Essien UR, Eneanya ND, Julien HM, Luo J et al (2021) Racial, ethnic, and socioeconomic inequities in glucagon-like peptide-1 receptor agonist use among patients with diabetes in the US
Several other conditions, including a history of pancreatitis, gallbladder disease, severe gastroparesis, severe kidney disease, diabetic retinopathy, and a history of an eating disorder, need extra clinical caution rather than being automatic exclusions
One of the first things many experience is a gradual reduction in appetite